IP Library › Granted Patent US 12,460,182
Granted Patent B2
US 12,460,182 · App. 17/612,441 · Granted Nov 4, 2025

Cell-containing pharmaceutical composition

Inventors: Takayuki Asahara (Kanagawa, JP); Amankeldi A. Salybekov (Kanagawa, JP); Makoto Seki (Tokyo, JP)
Assignee: CellAxia Inc.
C12N5/0645A61K40/10A61K40/17A61K40/22A61K40/24A61K40/416A61P29/00A61K2239/31A61K2239/38C12N2500/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,460,182
App. No.
17/612,441
Granted
Nov 4, 2025
Kind
B2
Abstract

A pharmaceutical composition containing a cell population with enriched M2 macrophage and a pharmaceutically acceptable carrier is provided. The composition is not trapped in the lungs when administered systemically, and accumulates at a disorder/inflammation site. Therefore, the pharmaceutical composition of the present invention is useful as an anti-inflammatory pharmaceutical composition.

Claims (5)

1 . A method for the treatment of an inflammatory disease, comprising administering an effective amount of cell population enriched in M2 macrophage to a target in need thereof, wherein the cell population comprises the M2 macrophage in a proportion of not less than 7%.

2 . The method according to claim 1 , wherein the cell population further comprises the M1 macrophage in a proportion of less than 10%.

3 . The method according to claim 1 , wherein the M2 macrophage is enriched by culturing body fluid-derived mononuclear cells in a serum-free medium, without medium change or passage.

4 . The method according to claim 1 , wherein the administration is systemic administration.

5 . The method according to claim 1 , wherein the inflammatory disease is an autoimmune disease.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2021
From: ASAHARA, TAKAYUKI; SALYBEKOV, AMANKELDI A.; SEKI, MAKOTO
To: CELLAXIA INC.
Reel/Frame 058155/0567 →
Continuity (1)
Related Publication 20220218744A1 · Jul 14, 2022
References Cited (28)
US 9844570B2 · Yoshida et al. · 2017 [cited by applicant]
US 10286014B2 · Asahara et al. · 2019 [cited by applicant]
US 10376544B2 · Yoshida et al. · 2019 [cited by applicant]
US 10639335B2 · Yoshida et al. · 2020 [cited by applicant]
US 20150196600A1 · Yoshida et al. · 2015 [cited by applicant]
US 20150238538A1 · Asahara et al. · 2015 [cited by applicant]
US 20170204374A1 · Iyoku et al. · 2017 [cited by applicant]
US 20180050067A1 · Yoshida et al. · 2018 [cited by applicant]
US 20190307806A1 · Yoshida et al. · 2019 [cited by applicant]
US 20210230553A1 · Iyoku et al. · 2021 [cited by applicant]
JP 6372782B2 · 2018 [cited by examiner]
WO 2014027684A1 · 2014 [cited by applicant]
WO 2014051154A1 · 2014 [cited by applicant]
WO 2016161462A1 · 2016 [cited by applicant]
WO WO2016185026A1 · 2016 [cited by examiner]
WO WO2018055153A1 · 2018 [cited by examiner]
Stemcell technologies “Immunocult-SF macrophage medium” product catalog (Year: 2017). [cited by examiner]
All in the Difference “understanding the key differences between disorder and disease” (Year: 2023). [cited by examiner]
Miller-Keane Encylopedia and Dictionary of Medicine, Nursing, and Allied Health. Seventh Edition (2003) (Year: 2025). [cited by examiner]
International Search Report issued Oct. 21, 2019 in International Application No. PCT/JP2019/032322. [cited by applicant]
Cheng et al., “Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis”, Cellular Immunology, 2017, vol. 311, pp. 46-53 (8 pages total). [cited by applicant]
Salybekov et al., “Regeneration-Associated Cells Improve Recovery from Myocardial Infarction through Enhanced Vasculogenesis, Anti-inflammation, and Cardiomyogenesis”, bioRxiv, 2018, http://dx.doi.org/10.1101/396101. [cited by applicant]
Salybekov et al., “Regeneration-associated cells improve recovery from myocardial infarction through enhanced vasculogenesis, anti-inflammation, and cardiomyogenesis”, PLOS ONE, 2018, vol. 13, No. 11, e0203244 pp. 1-24 … [cited by applicant]
Masuda et al., “Vasculogenic Conditioning of Peripheral Blood Mononuclear Cells Promotes Endothelial Progenitor Cell Expansion and Phenotype Transition of Anti-Inflammatory Macrophage and T Lymphocyte to Cells With Rege… [cited by applicant]
Fischer et al., “Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect”, Stem Cells and Development, 2009, vol. 18, No. 5, pp. 683-691 (9 pages total). [cited by applicant]
Morikawa et al., “Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow”, J. Exp. Mol., vol. 206, No. 11, pp. 2483-2496 (14 pages total). [cited by applicant]
Mabuchi et al., “LNGFR+THY-1+VCAM-1hi+ Cells Reveal Functionally Distinct Subpopulations in Mesenchymal Stem Cells”, Stem Cell Reports, 2013, vol. 1, pp. 152-165 (14 pages total). [cited by applicant]
Masuda et al., “Development of Serum-Free Quality and Quantity Control Culture of Colony-Forming Endothelial Progenitor Cell for Vasculogenesis”, Stem Cells Translational Medicine, 2012, vol. 1, pp. 160-171 (12 pages to… [cited by applicant]